1. Determining Triglyceride Reductions Needed for Clinical Impact in Severe Hypertriglyceridemia 
Jennifer B. Christian, PharmD, MPH, PhD, Bhakti Arondekar, BPharm, MBA, PhD, Erin K. Buysman, MS, Terry A. Jacobson, MD, Rose G. Snipes, MD, Ralph I. Horwitz, MD 
The American Journal of Medicine 
Volume 127, Issue 1, Pages e1 (January 2014)
DOI: /j.amjmed
Copyright © 2014 Elsevier Inc. Terms and Conditions

2. Figure 1 Patient selection.
The American Journal of Medicine  , e1DOI: ( /j.amjmed )
Copyright © 2014 Elsevier Inc. Terms and Conditions

3. Figure 2
Laboratory results stratified by follow-up triglyceride level (mg/dL).
The American Journal of Medicine  , e1DOI: ( /j.amjmed )
Copyright © 2014 Elsevier Inc. Terms and Conditions

4. Figure 3
Crude incidence rates (per 100 person-years) for clinical events in the follow-up period stratified by follow-up triglyceride level (mg/dL).
The American Journal of Medicine  , e1DOI: ( /j.amjmed )
Copyright © 2014 Elsevier Inc. Terms and Conditions

5. Figure 4
Adjusted IRRs* for clinical events in the follow-up period stratified by follow-up triglyceride level (mg/dL). Reference group is follow-up triglyceride levels ≥500 mg/dL.
The American Journal of Medicine  , e1DOI: ( /j.amjmed )
Copyright © 2014 Elsevier Inc. Terms and Conditions